TY  - JOUR
AU  - Gaasch, Aurélie
AU  - Marschner, Sebastian N
AU  - Hoegen-Saßmannshausen, Philipp
AU  - Sandrini, Elisabetta
AU  - Hörner-Rieber, Juliane
AU  - Andratschke, Nicolaus
AU  - Balermpas, Panagiotis
AU  - Boldrini, Luca
AU  - Romano, Angela
AU  - Reiner, Michael
AU  - Niyazi, Maximilian
AU  - Lindner, Lars
AU  - Weckbach, Ludwig
AU  - Fink, Nicola
AU  - Hagl, Christian
AU  - Belka, Claus
AU  - Corradini, Stefanie
TI  - Stereotactic heart ablative radiotherapy (SHARP): a prospective multicentric phase II trial.
JO  - Strahlentherapie und Onkologie
VL  - nn
SN  - 0179-7158
CY  - Heidelberg
PB  - Springer Medizin
M1  - DKFZ-2026-00258
SP  - nn
PY  - 2026
N1  - #DKTKZFB9# / epub
AB  - Cardiac tumors are exceedingly rare with metastatic involvement representing the most frequent form of malignancy within the heart. In patients presenting with inoperable primary or recurrent malignant cardiac sarcomas or cardiac/epicardial/pericardial metastases, stereotactic body radiotherapy (SBRT) serves as an alternative local treatment to surgery or may, in some cases, constitute the sole viable local treatment modality. To date, there are only case reports or small retrospective studies assessing SBRT dose and toxicity for cardiac SBRT. The goal of this prospective multicentric observational study is to systematically evaluate the feasibility, toxicity and outcome of magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) in the management of primary and secondary cardiac malignancies.The treatment is performed using MR-guided SBRT in five fractions on non-consecutive days (6-8 Gy per fraction prescribed to the 80
KW  - Cardiac (Other)
KW  - MR-guidance (Other)
KW  - MRgSBRT (Other)
KW  - Online adaptive (Other)
KW  - SBRT (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41615458
DO  - DOI:10.1007/s00066-026-02504-5
UR  - https://inrepo02.dkfz.de/record/309608
ER  -